On June 20th, Pfizer and Valneva unveiled the terms of their collaboration and licensing agreement for VLA15, a vaccine candidate against Lyme disease. Valneva is a French company specialized in …
Improving lives of Parkinson’s patients – Gerresheimer AG and the start-up Adamant Health are joining forces to develop a measurement technology and platform to optimize treatment administration for patients with …
EPIGENEXT will focus on the development of small molecule The clinical-stage pharmaceutical R&D company, Lead Pharma and Oxeltis, an independent medicinal chemistry service company, have just received a EUR 800,000 …
Flexible bags have their CMO in the US August Bioservices expands its offer – The numerous CMO-CDMOs in the United States offer filling services for intravenous solutions in glass or …
Stevanato Group and Owen Mumford have signed an agreement making Stevanato Group the exclusive manufacturing partner for its Aidaptus® auto-injector. The group, with over 70 years of experience, has all …
The medical device and diagnostics provider PHC has received European Union Medical Device Regulation RDM-EU certification for its APP-1000 motorized drug injection device. The device simplifies the administration of tumor …
Delpharm invests in Tours | The CDMO Delpharm confirms its strategy by investing in its manufacturing site in Tours, France. The project, initiated in April 2021, has resulted in a …
Catalent announced yesterday the acquisition of a biologics development and manufacturing facility. Owned by Vaccine Manufacturing and Innovation Centre UK Limited , the new facility is located near Oxford, UK, …
Partner of the pharmaceutical and diagnostic industry, SGH Healthcaring has just announced an investment of 8.2 M€ for the construction of a 650 sqm controlled atmosphere area on the Rovipharm …
Leader in drug containment, drug delivery and diagnostic solutions for the pharmaceutical industry, Stevanato Group delivers integrated portfolio of products, processes and services that meet customer needs form the development …
